glp 1 receptor agonists beyond their pancreatic effects GLP1 Agonists—Effects Obesity and Diabetes Understanding GLP-1 receptor agonists and

Drug Interactions and Cardiovascular Effects Common Drug Interactions with GLP-1 Medications When using GLP-1 receptor agonists to improve cardiovascular health, its crucial to understand how these medications interact with others

Discussion The current review explores the evolving role of GLP-1RAs in the management of various pain conditions, beyond their traditional application in metabolic diseases

Biochem Pharmacol 164:3444 Langlois JA, Mussolino ME, Visser M, Looker AC, Harris T, Madans J (2001) Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study

Phase 2 data showed participants losing up to 18.7% of body weight at the highest dose over 46 weeks

Renal impairment GLP-1 RAs are generally safe in patients with CKD and have demonstrated nephroprotective effects in the FLOW trial, where semaglutide significantly reduced the composite renal endpoint (hospitalization for acute kidney injury, sustained 50% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death) in patients with type 2 diabetes and CKD [15]